148 related articles for article (PubMed ID: 37949664)
1. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
3. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
[TBL] [Abstract][Full Text] [Related]
5. The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the
Chen WL; Pao E; Owens J; Glass I; Pritchard C; Shirts BH; Lockwood C; Mirzaa GM
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483878
[TBL] [Abstract][Full Text] [Related]
6. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
8. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
[TBL] [Abstract][Full Text] [Related]
9. Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP)--pure coincidence?
Döcker D; Schubach M; Menzel M; Spaich C; Gabriel HD; Zenker M; Bartholdi D; Biskup S
Eur J Hum Genet; 2015 Mar; 23(3):409-12. PubMed ID: 24939587
[TBL] [Abstract][Full Text] [Related]
10. Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials.
Garde A; Guibaud L; Goldenberg A; Petit F; Dard R; Roume J; Mazereeuw-Hautier J; Chassaing N; Lacombe D; Morice-Picard F; Toutain A; Arpin S; Boccara O; Touraine R; Blanchet P; Coubes C; Willems M; Pinson L; Van Kien PK; Chiaverini C; Giuliano F; Alessandri JL; Mathieu-Dramard M; Morin G; Bursztejn AC; Mignot C; Doummar D; Di Rocco F; Cornaton J; Nicolas C; Gautier E; Luu M; Bardou M; Sorlin A; Philippe C; Edery P; Rossi M; Carmignac V; Thauvin-Robinet C; Vabres P; Faivre L
Clin Genet; 2021 May; 99(5):650-661. PubMed ID: 33415748
[TBL] [Abstract][Full Text] [Related]
11. Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations.
Park HJ; Shin CH; Yoo WJ; Cho TJ; Kim MJ; Seong MW; Park SS; Lee JH; Sim NS; Ko JM
Orphanet J Rare Dis; 2020 Aug; 15(1):205. PubMed ID: 32778138
[TBL] [Abstract][Full Text] [Related]
12. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
Vahidnezhad H; Youssefian L; Uitto J
Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA vascular overgrowth syndromes: an update.
Hughes M; Hao M; Luu M
Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
[TBL] [Abstract][Full Text] [Related]
14. Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing.
Rasmussen M; Sunde L; Weigert KP; Bogaard PW; Lildballe DL
Am J Med Genet A; 2014 May; 164A(5):1318-21. PubMed ID: 24665065
[TBL] [Abstract][Full Text] [Related]
15. Clinical pitfalls in the diagnosis of segmental overgrowth syndromes: a child with the c.2740G > A mutation in PIK3CA gene.
Maguolo A; Antoniazzi F; Spano A; Fiorini E; Gaudino R; Mauro M; Cantalupo G; Biban P; Maitz S; Cavarzere P
Ital J Pediatr; 2018 Sep; 44(1):110. PubMed ID: 30231930
[TBL] [Abstract][Full Text] [Related]
16. Brain Abnormalities in PIK3CA-Related Overgrowth Spectrum: Physician, Patient, and Caregiver Experiences.
Dexheimer J; Mirzaa GM
Adv Ther; 2022 Sep; 39(9):3871-3880. PubMed ID: 35857185
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.
Piacitelli AM; Jensen DM; Brandling-Bennett H; Gray MM; Batra M; Gust J; Thaker A; Paschal C; Tsuchiya K; Pritchard CC; Perkins J; Mirzaa GM; Bennett JT
Am J Med Genet A; 2018 Nov; 176(11):2301-2308. PubMed ID: 30063105
[TBL] [Abstract][Full Text] [Related]
18. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
